MicrRNA-based mesothelioma test available from Rosetta Genomics

"Rosetta Genomics has announced that its microRNA-based test to diagnose mesothelioma is now commercially available to physicians. This molecularly based test is intended to help doctors in distinguishing between lung cancer and mesothelioma. The test is called miRview™ meso and is Rosetta Genomics’ third molecular diagnostic test to go on the market. " (2009-1-6)
Read more...